岭南急诊医学杂志
嶺南急診醫學雜誌
령남급진의학잡지
Lingnan Journal of Emergency Medicine
2015年
5期
366-368
,共3页
朱鹏程%林镇荣%陈庆超%杨锡泉%张琳
硃鵬程%林鎮榮%陳慶超%楊錫泉%張琳
주붕정%림진영%진경초%양석천%장림
前列地尔%心脏功能%心力衰竭%心室重构
前列地爾%心髒功能%心力衰竭%心室重構
전렬지이%심장공능%심력쇠갈%심실중구
alprostadil%cardiac function%cardiac failure%ventricular remodeling
目的:探讨前列地尔对心力衰竭患者心脏功能和心室重构的影响。方法:将2013年8月至2015年5月广东省潮州市饶平县华侨医院心内科收治的心力衰竭患者80例随机分为对照组和研究组各40例,两组年龄、病程、原发病和心室率等差异无显著性(P >0.05);对照组按常规治疗,研究组在对照组治疗的基础上加用前列地尔10 ug/次,每日1次,持续10-14 d,2周后比较两组治疗前后心脏功能和心室重构的变化。结果:与对照组相比,治疗后研究组的左室舒张末期内径缩小,左室射血分数增高,6 min步行距离延长,静息心率显著减慢(P均<0.01);研究组总有效率高(P <0.01),且无严重并发症发生。结论:应用前列地尔治疗心力衰竭安全、有效,能明显改善心脏功能和心室重构,值得临床推广应用。
目的:探討前列地爾對心力衰竭患者心髒功能和心室重構的影響。方法:將2013年8月至2015年5月廣東省潮州市饒平縣華僑醫院心內科收治的心力衰竭患者80例隨機分為對照組和研究組各40例,兩組年齡、病程、原髮病和心室率等差異無顯著性(P >0.05);對照組按常規治療,研究組在對照組治療的基礎上加用前列地爾10 ug/次,每日1次,持續10-14 d,2週後比較兩組治療前後心髒功能和心室重構的變化。結果:與對照組相比,治療後研究組的左室舒張末期內徑縮小,左室射血分數增高,6 min步行距離延長,靜息心率顯著減慢(P均<0.01);研究組總有效率高(P <0.01),且無嚴重併髮癥髮生。結論:應用前列地爾治療心力衰竭安全、有效,能明顯改善心髒功能和心室重構,值得臨床推廣應用。
목적:탐토전렬지이대심력쇠갈환자심장공능화심실중구적영향。방법:장2013년8월지2015년5월광동성조주시요평현화교의원심내과수치적심력쇠갈환자80례수궤분위대조조화연구조각40례,량조년령、병정、원발병화심실솔등차이무현저성(P >0.05);대조조안상규치료,연구조재대조조치료적기출상가용전렬지이10 ug/차,매일1차,지속10-14 d,2주후비교량조치료전후심장공능화심실중구적변화。결과:여대조조상비,치료후연구조적좌실서장말기내경축소,좌실사혈분수증고,6 min보행거리연장,정식심솔현저감만(P균<0.01);연구조총유효솔고(P <0.01),차무엄중병발증발생。결론:응용전렬지이치료심력쇠갈안전、유효,능명현개선심장공능화심실중구,치득림상추엄응용。
Objective:To explore the effect of alprostadil on cardiac function and ventricular remodeling of patients with cardiac failure. Method:80 patients with cardiac failure in Overseas Chinese Hospital of Raoping County were divided into research group (n=40) and control group (n=40) randomly from Aug 2013 to May 2015. The research group was treated by alprostadil based on the conventional methods in the control group. There were no differences in the baseline data including age, history, primary disease and ventricular rate between the two groups. Alprostadil was added 10 μg/d for 10-14 days in research group. The differences on cardiac function and ventricular remodeling were compared after 2 weeks after treatment between the two groups. Results:Compared with the control group,there were shorter left ventricular end diastolic diameter,larger left ventricular ejection fraction, longer walking distance in 6 minutes and slower resting heart rate,and higher the total effective rate in the research group,all P<0.01.There were no severe side actions in the research group. Conclusion:It is effective and safe in patients with cardiac failure treated by Alprostadil. Alprostadil could increase cardiac function and improve ventricular remodeling and could be used more popular in patients with cardiac failure.